OncoSec Medical to Present at 24th Annual Wall Street Analyst Forum Institutional Investor ConferenceBusiness Wire (Feb 25, 2014)
Business Wire (Feb 4, 2014)
Business Wire (Jan 14, 2014)
OncoSec Medical to Present at “TEN”; Noble Financial Capital Markets’ Tenth Annual Equity ConferenceBusiness Wire (Jan 13, 2014)
Business Wire (Jan 7, 2014)
OncoSec Medical Announces Positive Interim Data from Phase 2 Study of OMS-I100 in Metastatic MelanomaBusiness Wire (Dec 16, 2013)
Business Wire (Dec 12, 2013)
Oncosec Medical Incorporated develops novel ElectroOncology therapies that combine its proprietary electroporation delivery technology with a chemotherapeutic or novel DNA-based immunotherapeutics. Targeted delivery of these agents is designed to achieve selective destruction of cancerous... More
Monday, Dec 162013, 8:38 AM
Monday, Dec 162013, 8:38 AM| 2 Comments
- OncoSec Medical (ONCS) reports what it calls "positive interim data" from a Phase 2 study of OMS-I100 in metastatic melanoma.
- ONCS says the data "confirm the safety" of ImmunoPulse.
- Other results from patients treated with OMS-I100: "Positive response rates" (RECIST); 38.1% achieved OOR (e30% reduction in summed lesion size); six patients had a partial response; two patients achieved CR; additional two patients "exhibited clinically beneficial disease stabilization." (PR)
Tuesday, Oct 82013, 7:25 AM
Tuesday, Oct 82013, 7:25 AM| 4 Comments
- OncoSec Medical (ONCS.OB) says that combining ImmunoPulse DNA-based immunotherapy with anti-CTLA4 and anti-PD1 antibodies was effective in reducing tumors in a trial of 40 mice.
- While the mice were treated with ImmunoPulse alone, or in combination with anti-CTLA4, anti-PD1 or both, there was 100% regression of treated lesions in all of the animals, with none dying due to toxicity.
- OncoSec now intends to test various approaches in more aggressive melanoma models with a view to eventually carrying out human trials. (PR)
Monday, Jul 222013, 8:58 AM
Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.